Marshall Wace, LLP Glycomimetics Inc Transaction History

Marshall Wace, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.55 - $3.49 $521,770 - $714,109	204,616 Added 1588.02%	217,501 $652,000
Q4 2023 Feb 14, 2024	BUY	$1.13 - $2.54 $14,560 - $32,727	12,885 New	12,885 $30,000
Q2 2023 Aug 14, 2023	SELL	$1.21 - $2.08 $89,417 - $153,709	-73,899 Reduced 34.17%	142,400 $247,000
Q1 2023 May 15, 2023	BUY	$1.25 - $4.05 $9,197 - $29,799	7,358 Added 3.52%	216,299 $272,000
Q4 2022 Feb 14, 2023	BUY	$0.57 - $3.03 $119,096 - $633,091	208,941 New	208,941 $633,000
Q1 2019 May 14, 2019	SELL	$9.96 - $13.44 $1.58 Million - $2.13 Million	-158,262 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$8.47 - $14.71 $1.34 Million - $2.33 Million	158,262 New	158,262 $1.5 Million

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $12.1M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.